Literature DB >> 10319064

Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

A Telenti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10319064      PMCID： PMC1745329          DOI： 10.1136/thx.53.9.793

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  59 in total

1.  Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations.

Authors:  S Sreevatsan; K E Stockbauer; X Pan; B N Kreiswirth; S L Moghazeh; W R Jacobs; A Telenti; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Activity of amoxicillin/clavulanate in patients with tuberculosis.

Authors:  H F Chambers; T Kocagöz; T Sipit; J Turner; P C Hopewell
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

3.  Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

Authors:  N Mor; A Esfandiari
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium.

Authors:  K Mdluli; J Swanson; E Fischer; R E Lee; C E Barry
Journal:  Mol Microbiol       Date:  1998-03       Impact factor: 3.501

5.  NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis.

Authors:  L Miesel; T R Weisbrod; J A Marcinkeviciene; R Bittman; W R Jacobs
Journal:  J Bacteriol       Date:  1998-05       Impact factor: 3.490

6.  Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic.

Authors:  S Quan; H Venter; E R Dabbs
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

7.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol.

Authors:  R Condos; W N Rom; N W Schluger
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

Review 8.  The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Authors:  G J Alangaden; S A Lerner
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

9.  Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.

Authors:  D A Rozwarski; G A Grant; D H Barton; W R Jacobs; J C Sacchettini
Journal:  Science       Date:  1998-01-02       Impact factor: 47.728

10.  Role of embB in natural and acquired resistance to ethambutol in mycobacteria.

Authors:  F Alcaide; G E Pfyffer; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191
View more
  13 in total

Review 1.  Drug-resistant tuberculosis: what do we do now?

Authors:  A Telenti; M Iseman
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  Modern laboratory diagnosis of mycobacterial infections.

Authors:  S A Watterson; F A Drobniewski
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

3.  Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania.

Authors:  Daiva Bakonyte; Aurelija Baranauskaite; Jurate Cicenaite; Anaida Sosnovskaja; Petras Stakenas
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.

Authors:  Rosilene Fressatti Cardoso; Robert C Cooksey; Glenn P Morlock; Patricia Barco; Leticia Cecon; Francisco Forestiero; Clarice Q F Leite; Daisy N Sato; Maria de Lourdes Shikama; Elsa M Mamizuka; Rosario D C Hirata; Mario H Hirata
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance.

Authors:  N Galí; J Domínguez; S Blanco; C Prat; F Alcaide; P Coll; V Ausina
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

6.  Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.

Authors:  Feng Wang; Paras Jain; Gulcin Gulten; Zhen Liu; Yicheng Feng; Krishna Ganesula; Alifiya S Motiwala; Thomas R Ioerger; David Alland; Catherine Vilchèze; William R Jacobs; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

7.  Evaluation of Anyplex™ II MTB/MDR kit's performance to rapidly detect isoniazid and rifampicin resistant Mycobacterium tuberculosis from various clinical specimens.

Authors:  Nuntana Chumpa; Kamon Kawkitinarong; Suwatchareeporn Rotcheewaphan; Ajcharaporn Sawatpanich; Suthidee Petsong; Somying Tumwasorn; Gompol Suwanpimolkul
Journal:  Mol Biol Rep       Date:  2020-03-02       Impact factor: 2.316

8.  Identification of rifampin-resistant genotypes in Mycobacterium tuberculosis by PCR-reverse dot blot hybridization.

Authors:  Xueqiong Wu; Junxian Zhang; Lixue Chao; Jianqin Liang; Yang Lu; Hongmin Li; Yourong Yang; Yan Liang; Chuihuan Li
Journal:  Mol Biotechnol       Date:  2008-07-04       Impact factor: 2.695

9.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12

10.  Use of NMR metabolomics to analyze the targets of D-cycloserine in mycobacteria: role of D-alanine racemase.

Authors:  Steven Halouska; Ofelia Chacon; Robert J Fenton; Denise K Zinniel; Raul G Barletta; Robert Powers
Journal:  J Proteome Res       Date:  2007-11-03       Impact factor: 4.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.